Single dose of Pegylated interferon lambda significantly lowers Covid-19 related events: NEJM
Dr Gilmar Reis and team have found in a new study that single dose of pegylated interferon lambda used as early treatment in patients with COVID-19 was effective in lowering the total occurrences of hospitalization and ED visits. Further in these Covid-19-vaccinated outpatients, likelihood of hospitalization or an urgent care visit (observation for more than six hours) was considerably lower.
The findings of this study were published in The New England Journal of Medicine.
It is uncertain if a single dose of pegylated interferon lambda can prevent clinical events in outpatients with acute symptomatic coronavirus disease 2019 (Covid-19). Therefore, this study was conducted in order to assess the efficiency of pegylated interferon lambda in Covid-19.
In Brazil and Canada, a controlled, randomized, adaptive platform study enrolling mostly vaccinated persons with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was done. Outpatients with an acute clinical state compatible with Covid-19 who came within 7 days of the beginning of symptoms were given either pegylated interferon lambda (single subcutaneous injection, 180 g) or placebo (single injection or oral). Within 28 days of randomization, the key composite outcome was hospitalization (or transfer to a tertiary hospital) or an emergency department visit (observation for >6 hours) owing to Covid-19.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.